Annovis Bio, Inc. – NYSE:ANVS

Add to watchlist

$2.64

-2.62

-49.91%

Market closed

Open in 2 days

-56.66%

month

-56.66%

quarter

-73.14%

year

Market Cap	59.87M
Enterprise value	N/A

P/E	-4.59
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	4.03
PEG ratio	0.03
EPS	-5.13

Revenue	N/A
EBITDA	-42.72M
Income	-47.53M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Annovis Bio Stock Forecast

M Q Y

Last Year

$25.5

Potential upside: 865.90%

Analysts Price target
Financials & Ratios estimates

Annovis Bio, Inc. (NYSE:ANVS): Profit margin
Jun 2023	0	-9.53M
Sep 2023	0	-14.71M
Dec 2023	0	-22.21M
Mar 2024	0	-1.06M

Annovis Bio, Inc. (NYSE:ANVS): Debt to assets
Jun 2023	22816484	2.07M	9.09%
Sep 2023	10223106	3.56M	34.87%
Dec 2023	10208264	17.95M	175.93%
Mar 2024	7813295	11.16M	142.93%

Annovis Bio, Inc. (NYSE:ANVS): Cash Flow
Jun 2023	-9.60M	8.57M
Sep 2023	-6.43M	0
Dec 2023	-9.36M	8.76M
Mar 2024	-7.03M	4.41M

Annovis Bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Annovis Bio, Inc. (NYSE:ANVS): Employee count
Aug 2023	5
Sep 2023	5
Oct 2023	5
Nov 2023	5
Dec 2023	5
Jan 2024	5
Feb 2024	5
Mar 2024	5
Apr 2024	5
May 2024	6
Jun 2024	6
Jul 2024	6

Annovis Bio
Hedge Funds Holdings Q1 2023

4.71% -4.36%

of ANVS is owned by hedge funds

14 -8

hedge funds hold ANVS stock

384.62K -356.28K

shares is hold by hedge funds

ANVS hedge funds holdings changes

Annovis Bio, Inc. (NYSE:ANVS): Insider trades (number of shares)
Period	Buy	Sel
Aug 2021	500	0
Oct 2021	23181	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	6 Feb 2023	MACCECCHINI MARIA-LUISA director, 10 percent owner, office.. director, 10 percent owner, off..	Stock Option (right to buy)	52,755	$0.14	$7,386
Option	6 Feb 2023	MACCECCHINI MARIA-LUISA director, 10 percent owner, office.. director, 10 percent owner, off..	Common Stock	52,755	$0.14	$7,386
Option	14 Jan 2022	MACCECCHINI MARIA-LUISA director, 10 percent owner, office.. director, 10 percent owner, off..	Stock Option (right to buy)	32,959	$0.14	$4,614
Option	14 Jan 2022	MACCECCHINI MARIA-LUISA director, 10 percent owner, office.. director, 10 percent owner, off..	Common Stock	32,959	$0.14	$4,614
Option	4 Jan 2022	HOFFMAN MICHAEL B director, 10 percent owner director, 10 percent owner	Stock Option (right to buy)	7,142	$0.25	$1,786
Option	4 Jan 2022	HOFFMAN MICHAEL B director, 10 percent owner director, 10 percent owner	Common Stock	37,142	$2.32	$86,169
Purchase	12 Oct 2021	WHITE MARK K. director director	Common Stock	5,000	$27.4	$137,000
Purchase	11 Oct 2021	BRUCK CLAUDINE director director	Common Stock	181	$27.66	$5,006
Purchase	11 Oct 2021	MACCECCHINI MARIA-LUISA director, 10 percent owner, office.. director, 10 percent owner, off..	Common Stock	18,000	$27.61	$496,980
Purchase	19 Aug 2021	MCCARTHY REID	Common Stock, $0.0001 par value	500	$37.61	$18,805

Status	Patent	Filling date	Issue date
Grant	Grant Utility: (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration Filling date: 17 Aug 2020 Issue date: 2 Aug 2022	17 Aug 2020	2 Aug 2022
Grant	Grant Utility: (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration Filling date: 17 Aug 2020 Issue date: 12 Jul 2022	17 Aug 2020	12 Jul 2022
Grant	Grant Utility: (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration Filling date: 17 Aug 2020 Issue date: 5 Jul 2022	17 Aug 2020	5 Jul 2022
Grant	Grant Utility: (3AR)-1,3A,8-trimethyl-1,2,3,3A,8,8A-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration Filling date: 8 Jul 2019 Issue date: 24 Aug 2021	8 Jul 2019	24 Aug 2021
Application	Application (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION Filling date: 17 Aug 2020 Issue date: 1 Apr 2021	17 Aug 2020	1 Apr 2021
Application	Application (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION Filling date: 17 Aug 2020 Issue date: 3 Dec 2020	17 Aug 2020	3 Dec 2020
Application	Application (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION Filling date: 17 Aug 2020 Issue date: 3 Dec 2020	17 Aug 2020	3 Dec 2020

Annovis Bio
Executives

Insider	Age	Since	Compensation
Dr. Maria L. MacCecchini Ph.D. (1951) Founder, Chief Executive Officer, Pres & Director	74		$420,000
Mr. Jeffrey B. McGroarty CPA (1969) Chief Financial Officer	56		$300,000

Annovis Bio
Latest News

Thursday, 5 December 2024
08:30	Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace	globenewswire.com
Wednesday, 4 December 2024
14:21	/C O R R E C T I O N -- Today's Marketplace/	prnewswire.com
Monday, 25 November 2024
08:00	Annovis to Host Year-End Investor Webcast on December 11, 2024	globenewswire.com
Thursday, 31 October 2024
08:00	IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio	globenewswire.com
Tuesday, 15 October 2024
08:00	FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs	globenewswire.com
Thursday, 3 October 2024
08:30	Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases	globenewswire.com
Wednesday, 2 October 2024
08:30	Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations	globenewswire.com
Thursday, 5 September 2024
08:00	Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Tuesday, 6 August 2024
08:00	Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist	globenewswire.com
Wednesday, 3 July 2024
10:10	Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study	zacks.com
Tuesday, 2 July 2024
16:45	Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?	investorplace.com
13:57	Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial	marketwatch.com
Wednesday, 26 June 2024
08:00	Annovis Bio Files Patent for New Composition of Matter for Buntanetap	globenewswire.com
Tuesday, 11 June 2024
08:00	Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients	globenewswire.com
Tuesday, 28 May 2024
10:56	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet	zacks.com
Tuesday, 21 May 2024
07:30	Annovis Announces New Publication in a Peer-Reviewed Journal	globenewswire.com
Friday, 17 May 2024
11:00	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors	businesswire.com
Thursday, 16 May 2024
19:02	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors	businesswire.com
15:09	The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors	businesswire.com
Monday, 13 May 2024
07:30	Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results	globenewswire.com
Thursday, 9 May 2024
20:43	Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box	Seeking Alpha
Monday, 29 April 2024
10:30	Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial	Reuters
Wednesday, 24 April 2024
10:56	Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade	Zacks Investment Research
Monday, 8 April 2024
10:56	Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?	Zacks Investment Research
Thursday, 21 March 2024
10:56	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet	Zacks Investment Research
Friday, 15 March 2024
09:11	$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year	24/7 Wall Street
Wednesday, 6 March 2024
15:33	Sell Signal: 3 Stocks to Unload Before the Bubble Bursts	InvestorPlace
Monday, 12 February 2024
16:06	3 Growth Stocks to Sell in February Before They Bottom	InvestorPlace
09:06	Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects	Seeking Alpha
Tuesday, 5 December 2023
03:58	Alzheimer's Disease Drug Development: Another Lost Year	Seeking Alpha

Ideas & Opinions

Seeking Alpha 8 Jul 2024

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Seeking Alpha 30 Jun 2024

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Seeking Alpha 10 May 2024

Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
Seeking Alpha 2 May 2024

Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market
Seeking Alpha 2 May 2024

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
Seeking Alpha 12 Feb 2024

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Seeking Alpha 20 Jan 2024

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Seeking Alpha 5 Dec 2023

Alzheimer's Disease Drug Development: Another Lost Year
Seeking Alpha 16 Oct 2023

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Seeking Alpha 28 Jun 2023

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Frequently Asked Questions (FAQ)

What's the price of Annovis Bio stock today?

One share of Annovis Bio stock can currently be purchased for approximately $2.64.
When is Annovis Bio's next earnings date?

Unfortunately, Annovis Bio's (ANVS) next earnings date is currently unknown.
Does Annovis Bio pay dividends?

No, Annovis Bio does not pay dividends.
How much money does Annovis Bio make?

Annovis Bio has a market capitalization of 59.87M.
What is Annovis Bio's stock symbol?

Annovis Bio, Inc. is traded on the NYSE under the ticker symbol "ANVS".
What is Annovis Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Annovis Bio?

Shares of Annovis Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Annovis Bio's key executives?
Annovis Bio's management team includes the following people:
- Dr. Maria L. MacCecchini Ph.D. Founder, Chief Executive Officer, Pres & Director(age: 74, pay: $420,000)
- Mr. Jeffrey B. McGroarty CPA Chief Financial Officer(age: 56, pay: $300,000)
Is Annovis Bio founder-led company?

Yes, Annovis Bio is a company led by its founder Dr. Maria L. MacCecchini Ph.D..
How many employees does Annovis Bio have?

As Jul 2024, Annovis Bio employs 6 workers, which is 20% more then previous quarter.
When Annovis Bio went public?

Annovis Bio, Inc. is publicly traded company for more then 5 years since IPO on 29 Jan 2020.
What is Annovis Bio's official website?

The official website for Annovis Bio is annovisbio.com.
Where are Annovis Bio's headquarters?

Annovis Bio is headquartered at 1055 Westlakes Drive, Berwyn, PA.
How can i contact Annovis Bio?

Annovis Bio's mailing address is 1055 Westlakes Drive, Berwyn, PA and company can be reached via phone at +61 7273913.
What is Annovis Bio stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Annovis Bio in the last 12 months, the avarage price target is $25.5. The average price target represents a 865.90% change from the last price of $2.64.

Annovis Bio, Inc.

annovisbio.com

Exchange:

NYSE

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

+61 7273913

1055 Westlakes Drive
Berwyn, PA 19312

CIK: 0001477845
ISIN: US03615A1088
CUSIP: 03615A108